Top

Published in:

Open Access 01-08-2019 | Insulins | Commentary

Results of Insulin Therapy in Type 2 Diabetes Mellitus Patients in the Czech Republic: Do They Reflect the Current Status in Other Countries?

Authors: Jan Brož, Denisa Janíčková Ždárská, Jana Urbanová

Published in: Diabetes Therapy | Issue 4/2019

Abstract

The results of two large multicentric, observational and cross-sectional studies (the DIAINFORM study and BALI study) reflecting routine clinical practice for insulin treatment in type 2 diabetes mellitus in the Czech Republic were published recently. In this commentary, we analyze these results and compare them with the findings of similar studies conducted in other countries within the last decade. The analysis focuses on achievement of glycated hemoglobin goals, insulin dosage and frequency of hypoglycemia.

Brož J, Janíčková Žďárská D, Urbanová J, et al. Current level of glycemic control and clinical inertia in subjects using insulin for the treatment of type 1 and type 2 diabetes in the Czech Republic and the Slovak Republic: results of a multinational, multicentre observational survey (DIAINFORM). Diabetes Ther. 2018;9:1897–1906. https://doi.org/10.1007/s13300-018-0485-2.CrossRefPubMedPubMedCentral

Brož J, Janíčková Ždárská D, Štěpánová R, et al. Addition of basal insulin to oral antidiabetic agents in patients with inadequately controlled type 2 diabetes leads to improved HbA1c levels: metabolic control, frequency of hypoglycemia, and insulin titration analysis as results of a prospective observational study (BALI Study). Diabetes Ther. 2019;10(2):663–72. https://doi.org/10.1007/s13300-019-0584-8 CrossRefPubMedPubMedCentral

Selvin E, Parrinello ChM, Daya N, Bergenstal RM. Trends in insulin use and diabetes control in the US: 1988–1994 and 1999–2012. Diabetes Care. 2016;39(3):e33–5. https://doi.org/10.2337/dc15-2229.CrossRefPubMed

Pablos-Velasco P, Parhofer KG, Bradley C, et al. Current level of glycaemic control and its associated factors in patients with type 2 diabetes across Europe: data from the PANORAMA study. Clin Endocrinol. 2014;80:47–56.CrossRef

Shan S, Gu L, Lou Q, et al. Evaluation of glycemic control in patients with type 2 diabetes mellitus in Chinese communities: a cross-sectional study. Clin Exp Med. 2017;17(1):79–84. https://doi.org/10.1007/s10238-015-0406-x.CrossRefPubMed

Meneghini LF, Mauricio D, Orsi E, et al. The diabetes unmet need with basal insulin evaluation (DUNE) study in type 2 diabetes: achieving HbA(1c) targets with basal insulin in a real-world setting. Diabetes Obes Metab. 2019;21(6):1429–36. https://doi.org/10.1111/dom.13673.CrossRefPubMed

American Diabetes Association. Standards of medical care in diabetes—2017: summary of revisions. Diabetes Care. 2017;40[Suppl 1]:S4–5.CrossRef

Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–62. https://doi.org/10.2337/dc14-0991.CrossRefPubMed

Rosenstock J, Hollander P, Bhargava A, et al. Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: a randomized, double-blind controlled trial (the ELEMENT 2 study). Diabetes Obes Metab. 2015;17(8):734–41. https://doi.org/10.1111/dom.12482.CrossRefPubMed

10.

Riebenfeld D, Spirk D, Mathis A, et al. Treatment intensification with insulin glargine in patients with inadequately controlled type 2 diabetes improves glycaemic control with a high treatment satisfaction and no weight gain. Swiss Med Wkly. 2015;145:w14114. https://doi.org/10.4414/smw.2015.14114.CrossRefPubMed

11.

Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017;43(6):501–11. https://doi.org/10.1016/j.diabet.2017.06.003.CrossRefPubMed

12.

Haluzik M, Kretowski A, Strojek K, et al. Perspectives of patients with insulin-treated type 1 and type 2 diabetes on hypoglycemia: results of the HAT observational study in Central and Eastern European Countries. Diabetes Ther. 2018;9:727–41. https://doi.org/10.1007/s13300-018-0388-2.CrossRefPubMedPubMedCentral

13.

Blonde L, Meneghini L, Peng XV, et al. Probability of achieving glycemic control with basal insulin in patients with type 2 diabetes in real-world practice in the USA. Diabetes Ther. 2018;9(3):1347–58. https://doi.org/10.1007/s13300-018-0413-5.CrossRefPubMedPubMedCentral

14.

Mauricio D, Meneghini L, Seufert J, et al. Glycaemic control and hypoglycaemia burden in patients with type 2 diabetes initiating basal insulin in Europe and the USA. Diabetes Obes Metab. 2017;19(8):1155–64. https://doi.org/10.1111/dom.12927.CrossRefPubMedPubMedCentral

15.

Chien MN, Chen YL, Hung YJ, et al. Glycemic control and adherence to basal insulin therapy in Taiwanese patients with type 2 diabetes mellitus. J Diabetes Investig. 2016;7(6):881–8. https://doi.org/10.1111/jdi.12532.CrossRefPubMedPubMedCentral

16.

Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R, ATLANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282–8.CrossRef

17.

Title: Results of Insulin Therapy in Type 2 Diabetes Mellitus Patients in the Czech Republic: Do They Reflect the Current Status in Other Countries?
Authors: Jan Brož
Denisa Janíčková Ždárská
Jana Urbanová
Publication date: 01-08-2019
Publisher: Springer Healthcare
Keywords: Insulins
Oral Antidiabetic Drugs
Hypoglycemia
Diabetes
Insulins
Type 2 Diabetes
Published in: Diabetes Therapy / Issue 4/2019
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI: https://doi.org/10.1007/s13300-019-0637-z

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Results of Insulin Therapy in Type 2 Diabetes Mellitus Patients in the Czech Republic: Do They Reflect the Current Status in Other Countries?

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of Plasma Glucose Control Compared with T2DM

Pancreatitis Incidence in the Exenatide BID, Exenatide QW, and Exenatide QW Suspension Development Programs: Pooled Analysis of 35 Clinical Trials

Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2)

Short-Term Cost-Effectiveness of Switching to Insulin Degludec in Japanese Patients with Type 2 Diabetes Receiving Basal–Bolus Therapy

Using Clinical Indices to Distinguish MODY2 (GCK Mutation) and MODY3 (HNF1A Mutation) from Type 1 Diabetes in a Young Chinese Population

BE-SMART (Basal Early Strategies to Maximize HbA1c Reduction with Oral Therapy): Expert Opinion

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page